Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patents from the Tuschl II Patent Estate Broadly Covering RNAi Therapeutics
Posted on November 26, 2012 at 09:17 AM EST
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for three patent applications from the companyÂ’s exclusively held Tuschl II patent estate.